CD8-targeted PET imaging of tumor-infiltrating T cells in patients with cancer: A phase I first-in-humans study of (89)Zr-Df-IAB22M2C, a radiolabeled anti-CD8 minibody Journal Article

   

Authors:	Farwell, M. D.; Gamache, R. F.; Babazada, H.; Hellmann, M. D.; Harding, J. J.; Korn, R.; Mascioni, A.; Le, W.; Wilson, I.; Gordon, M. S.; Wu, A. M.; Ulaner, G. A.; Wolchok, J. D.; Postow, M. A.; Pandit-Taskar, N.
Article Title:	CD8-targeted PET imaging of tumor-infiltrating T cells in patients with cancer: A phase I first-in-humans study of (89)Zr-Df-IAB22M2C, a radiolabeled anti-CD8 minibody
Abstract:	There is a need for in vivo diagnostic imaging probes that can noninvasively measure tumor-infiltrating CD81 leukocytes. Such imaging probes could be used to predict early response to cancer immunotherapy, help select effective single or combination immunotherapies, and facilitate the development of new immunotherapies or immunotherapy combinations. This study was designed to optimize conditions for performing CD8 PET imaging with 89Zr-Df-IAB22M2C and determine whether CD8 PET imaging could provide a safe and effective noninvasive method of visualizing the whole-body biodistribution of CD81 leukocytes. Methods: We conducted a phase 1 first-inhumans PET imaging study using an anti-CD8 radiolabeled minibody, 89Zr-Df-IAB22M2C, to detect whole-body and tumor CD81 leukocyte distribution in patients with metastatic solid tumors. Patients received 111 MBq of 89Zr-Df-IAB22M2C followed by serial PET scanning over 5-7 d. A 2-stage design included a dose-escalation phase and a dose-expansion phase. Biodistribution, radiation dosimetry, and semiquantitative evaluation of 89Zr-Df-IAB22M2C uptake were performed in all patients. Results: Fifteen subjects with metastatic melanoma, non-small cell lung cancer, and hepatocellular carcinoma were enrolled. No drug-related adverse events or abnormal laboratory results were noted except for a transient increase in antidrug antibodies in 1 subject. 89Zr-Df-IAB22M2C accumulated in tumors and CD8- rich tissues (e.g., spleen, bone marrow, nodes), with maximum uptake at 24-48 h after injection and low background activity in CD8-poor tissues (e.g., muscle and lung). Radiotracer uptake in tumors was noted in 10 of 15 subjects, including 7 of 8 subjects on immunotherapy, 1 of 2 subjects on targeted therapy, and 2 of 5 treatment-naïve subjects. In 3 patients with advanced melanoma or hepatocellular carcinoma on immunotherapy, posttreatment CD8 PET/CT scans demonstrated increased 89Zr-Df-IAB22M2C uptake in tumor lesions, which correlated with response. Conclusion: CD8 PET imaging with 89Zr-Df- IAB22M2C is safe and has the potential to visualize the whole-body biodistribution of CD81 leukocytes in tumors and reference tissues, and may predict early response to immunotherapy. © 2022 by the Society of Nuclear Medicine and Molecular Imaging.
Keywords:	immunotherapy; pet imaging; minibody; 89zr-df-iab22m2c; cd81 t cell
Journal Title:	Journal of Nuclear Medicine
Volume:	63
Issue:	5
ISSN:	0161-5505
Publisher:	Society of Nuclear Medicine
Date Published:	2022-05-01
Start Page:	720
End Page:	726
Language:	English
DOI:	10.2967/jnumed.121.262485
PUBMED:	34413145
PROVIDER:	scopus
PMCID:	PMC9051598
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85129501589&doi=10.2967%2fjnumed.121.262485&partnerID=40&md5=cff9a4fe95e05e5937081d5f893d5e6e
Notes:	Article -- Export Date: 1 June 2022 -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/194790